FDA expectations for the next fiscal year of ANDA approvals and submissions appear to be underestimated.
At the same time, the Office of Generic Drugs is expecting median approval times to drop by several months, indicating a belief that the agency will make significant strides in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?